Gastric Cancer
Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. Apr 7, 2008; 14(13): 1990-1996
Published online Apr 7, 2008. doi: 10.3748/wjg.14.1990
Figure 1
Figure 1 Syndecan-1 expression. A: Syndecan-1 was negatively (+) expressed in gastric carcinoma. Sp method. (× 250); B: Syndecan-1 was highly expressed (++) in non-tumor gastric mucosa (× 250).
Figure 2
Figure 2 E-cadherin expressions. A: E-cadherin was negatively (+) expressed in gastric carcinoma (Magnification × 250); B: E-cadherin was highly expressed (++) in non-tumor gastric mucosa (× 250).
Figure 3
Figure 3 Integrin β3 expression. A: Integrin β3 was highly expressed (+++) in gastric carcinoma (× 250); B: Integrin β3 was negatively (+) expressed in non-tumor gastric mucosa (× 250).
Figure 4
Figure 4 Correlation between syndecan-1, E-cadherin and integrin β3 expressions and the survival time. A: Survival curves by the Kaplan-Meier method. Long-rank test revealing a significant difference between negative and positive expression of Syndecan-1 (P < 0.05); B: Survival curves by Kaplan-Meier method. Long-rank test revealing a significant difference between negative and positive expression of E-cadherin (P < 0.05); C: Survival curves by the Kaplan-Meier method. There was a significant difference in Long-rank test between positive and negative expression of integrin β3 (P < 0.05).